Logo Image
|Articles|April 16, 2015

India May Take WTO Action after EMA Drug Suspension

Author(s)News Update

April 16, 2015.

Reuters reports

that India may go to the World Trade Organization (WTO) if the European Union (EU) does not reconsider its decision to suspend the sale of about 700 generic drugs that were approved based on clinical trials by GVK Biosciences Pvt Ltd.   The European Medicines Agency (EMA) suspension became effective in January, a month after France, Germany, Belgium and Luxembourg suspended the sale of 25 generic drugs that were approved based on trials conducted by GVK Biosciences.   Drugs suspended by the EMA include those made by U.S. firms Mylan Inc and Abbott Laboratories, as well as large Indian companies such as Lupin Ltd and Dr Reddy's Laboratories.   After an appeal by the company, the Indian government set up a panel of experts last year to investigate the matter and found no manipulation, GVK Biosciences CEO Manni Kantipudi told Reuters.   If the suspension is not reconsidered New Delhi could take action at the WTO.  

http://www.reuters.com/article/2015/04/15/us-gvk-bio-india-idUSKBN0N60IJ20150415

Related to this article

View more
How QMM Can Help the C-Suite See a $100 Million Problem Early
How QMM Can Help the C-Suite See a $100 Million Problem Early
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Read more